Table 6.
Group comparisons of symptoms from the Kansas City Cardiomyopathy Questionnaire (KCCQ)
| Ubiquinol vs Placebo* | d-ribose vs Placebo† | Ubiquinol and d-ribose vs Placebo‡ | Ubiquinol and d-ribose vs Ubiquinol§ | |
|---|---|---|---|---|
| Change in KCCQ: physical limitation | ||||
| Difference | 24.85 | 29.54 | 21.33 | −3.52 |
| Degrees of freedom | 70 | 68 | 68 | 66 |
| Uncorrected p value¶ | <0.0001 | <0.0001 | 0.0010 | 0.5609 |
| Corrected p value** | 0.0004 | <0.0001 | 0.0040 | 0.9999 |
| 98.75% confidence interval†† | (9.50, 40.20) | (14.31, 44.77) | (5.43, 37.23) | (−18.96, 11.93) |
| t value | 4.15 | 4.98 | 3.44 | −0.58 |
| Change in KCCQ: symptom stability | ||||
| Difference | 17.42 | 20.20 | 8.83 | −8.59 |
| Degrees of freedom | 71 | 69 | 69 | 66 |
| Uncorrected p value¶ | 0.0083 | 0.0027 | 0.1843 | 0.2375 |
| Corrected p value** | 0.0333 | 0.0109 | 0.7374 | 0.9501 |
| 98.75% confidence interval†† | (0.97, 33.88) | (3.54, 36.85) | (−8.06, 25.72) | (−27.11, 9.92) |
| t value | 2.71 | 3.11 | 1.34 | −1.19 |
| Change in KCCQ: symptom frequency | ||||
| Difference | 20.78 | 22.30 | 11.44 | −9.34 |
| Degrees of freedom | 71 | 69 | 69 | 66 |
| Uncorrected p value¶ | 0.0007 | 0.0007 | 0.0952 | 0.1385 |
| Corrected p value** | 0.0026 | 0.0030 | 0.3810 | 0.5541 |
| 98.75% confidence interval†† | (5.85, 35.71) | (6.10, 38.51) | (−5.91, 28.79) | (−25.34, 6.66) |
| t value | 3.57 | 3.53 | 1.69 | −1.50 |
| Change in KCCQ: symptom burden | ||||
| Difference | 18.36 | 21.10 | 14.28 | −4.08 |
| Degrees of freedom | 71 | 69 | 69 | 66 |
| Uncorrected p value¶ | 0.0025 | 0.0033 | 0.0248 | 0.4454 |
| Corrected p value** | 0.0098 | 0.0131 | 0.0993 | 0.9999 |
| 98.75% confidence interval†† | (3.38, 33.35) | (3.33, 38.86) | (−1.68, 30.25) | (−17.74, 9.58) |
| t value | 3.14 | 3.05 | 2.29 | −0.77 |
| Change in KCCQ: Total Symptom Score | ||||
| Difference | 19.57 | 21.70 | 12.86 | −6.71 |
| Degrees of freedom | 71 | 69 | 69 | 66 |
| Uncorrected p value¶ | 0.0006 | 0.0009 | 0.0349 | 0.2078 |
| Corrected p value** | 0.0023 | 0.0034 | 0.1397 | 0.8314 |
| 98.75% confidence interval†† | (5.65, 33.50) | (5.74, 37.66) | (−2.47, 28.19) | (−20.26, 6.84) |
| t value | 3.60 | 3.49 | 2.15 | −1.27 |
| Change in KCCQ: self efficacy | ||||
| Difference | 8.36 | 12.37 | 15.78 | 7.42 |
| Degrees of freedom | 71 | 69 | 69 | 66 |
| Uncorrected p value¶ | 0.1374 | 0.0264 | 0.0203 | 0.2787 |
| Corrected p value** | 0.5494 | 0.1056 | 0.0813 | 0.9999 |
| 98.75% confidence interval†† | (−5.90, 22.61) | (−1.61, 26.35) | (−1.26, 32.82) | (−10.03, 24.88) |
| t value | 1.50 | 2.27 | 2.38 | 1.09 |
| Change in KCCQ: quality of life | ||||
| Difference | 15.46 | 21.94 | 14.61 | −0.84 |
| Degrees of freedom | 71 | 69 | 69 | 66 |
| Uncorrected p value¶ | 0.0088 | 0.0005 | 0.0129 | 0.8856 |
| Corrected p value** | 0.0354 | 0.0018 | 0.0517 | 0.9999 |
| 98.75% confidence interval†† | (0.74, 30.17) | (6.66, 37.22) | (−0.08, 29.30) | (−15.85, 14.17) |
| t value | 2.69 | 3.68 | 2.55 | −0.14 |
| Change in KCCQ: social limitation | ||||
| Difference | 23.41 | 26.50 | 15.83 | −7.58 |
| Degrees of freedom | 66 | 65 | 63 | 63 |
| Uncorrected p value¶ | 0.0018 | 0.0004 | 0.0303 | 0.2794 |
| Corrected p value** | 0.0072 | 0.0016 | 0.1213 | 0.9999 |
| 98.75% confidence interval†† | (4.93, 41.88) | (8.28, 44.73) | (−2.54, 34.19) | (−25.45, 10.29) |
| t value | 3.25 | 3.74 | 2.22 | −1.09 |
| Change in KCCQ: overall summary | ||||
| Difference | 22.50 | 26.17 | 17.63 | −4.86 |
| Degrees of freedom | 65 | 64 | 62 | 63 |
| Uncorrected p value¶ | <0.0001 | <0.0001 | 0.0021 | 0.3354 |
| Corrected p value** | 0.0002 | <0.0001 | 0.0083 | 0.9999 |
| 98.75% confidence interval†† | (9.26, 35.74) | (12.60, 39.73) | (3.52, 31.74) | (−17.74, 8.02) |
| t value | 4.37 | 4.96 | 3.22 | −0.97 |
The difference in changes was calculated as ubiquinol group minus Placebo group.
The difference in changes was calculated as d-ribose group minus Placebo group.
The difference in changes was calculated as ubiquinol and d-ribose group minus Placebo group.
The difference in changes was calculated as ubiquinol and d-ribose group minus ubiquinol group.
p values should be compared to the corrected significance level of 0.05/4=0.0125 because of a Bonferroni correction for 4 comparisons.
p values corrected for 4 comparisons.
Confidence intervals are based on a nominal level of 95% confidence and 4 comparisons. Therefore, a Bonferroni corrected 98.75% level was used.
ATP = Adenosine Triphosphate; BNP = B–type natriuretic peptide; E/e′ = E to early diastolic mitral annular. tissue velocity; KCCQ = Kansas City Cardiomyopathy Questionnaire; RLU = Relative Light Units; SD = standard deviation; 6MWT = 6 min Walk Test.
Values are mean ± standard deviation and mean.